Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267667 | 0.93 | CYP3A4 (0.53) | CYP3A4CYP2C19CYP2D6CYP2C9LCK | |
| SCHEMBL1267657 | 0.91 | CYP3A4 (0.49) | CYP3A4CYP2C19CYP2D6CYP2C9LCK | |
| SCHEMBL1267855 | 0.90 | CYP3A4 (0.49) | CYP3A4CYP2C19CYP2D6CYP2C9LCK | |
| SCHEMBL1266887 | 0.90 | CYP3A4 (0.43) | CYP3A4CYP2C19CYP2D6CYP2C9LCK | |
| SCHEMBL1267144 | 0.90 | CYP3A4 (0.53) | CYP3A4CYP2C19CYP2D6CYP2C9LCK | |
| SCHEMBL1267878 | 0.89 | CYP3A4 (0.44) | CYP3A4CYP2C19CYP2D6CYP2C9LCK | |
| SCHEMBL1267332 | 0.87 | CYP3A4 (0.47) | CYP3A4CYP2C19CYP2D6CYP2C9LCK | |
| SCHEMBL1267607 | 0.87 | CYP3A4 (0.46) | CYP3A4CYP2C19CYP2D6CYP2C9LCK | |
| SCHEMBL1266958 | 0.87 | CYP2C9 (0.50) | CYP3A4CYP2C19CYP2D6CYP2C9LCK | |
| SCHEMBL1267939 | 0.86 | CYP3A4 (0.45) | CYP3A4CYP2C19CYP2D6CYP2C9LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605787-A | Compounds that modulate c-fms and/or c-kit activity and uses thereof | PLEXXIKON INC (US) | 2009-12-16 | — | — | CN | claimed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | claimed |
| WO-2008063888-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-9550768-B2 | Kinase modulation and indications therefor | PLEXXIKON INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063888-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063888-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CYP3A4 3847/4885CYP2C19 3327/4885CYP2D6 3987/4885 |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | CYP3A4 3847/4885CYP2C19 3327/4885CYP2D6 3987/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CYP3A4 3868/4885CYP2C19 3359/4885CYP2D6 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.